AMA Press Releases published a current U.S. medical or healthcare update on November 10, 2026. The story is receiving priority because the agent rated it as a timely, high-impact topic in drugs, treatments and FDA action. This article summarizes the verified source material and separates confirmed facts from issues that still need to be watched.
What happened?
AI tools can help doctors to improve healthcare, but new policy clarifies boundaries around the tech. Learn about other steps the AMA is taking on AI.
Key facts from the source
- The Food and Drug Administration (FDA) has authorized more than 1,450 AI-enabled medical devices as of December 2025 and—no different from say, from an inherent problem in an MRI machine—physicians should not bear responsibility for defects.
- Established product-liability law already holds that when a medical device fails because of a defect in the design, manufacturing or warnings, the manufacturer bears liability for the resulting patient harm—not the physician.
- That AI vendors and manufacturers be held to the same product liability standards as manufacturers of other medical devices including but not limited to liability for design defects and failure to provide adequate instructions or warnings.
- That when a health system, hospital, payer or other entity mandates the use of a specific AI tool and that tool produces an error resulting in patient harm, the mandating entity and the AI vendor bear the liability, and the physician who was required to use the tool and exercised appropriate clinical judgment is not liable for errors originating in the mandated product.
- AI—often called artificial intelligence—can help doctors with clinical tasks, but it cannot be granted physician licensure, professional titles or certification to practice medicine, says new policy adopted at the 2026 AMA Interim Meeting.
Why this matters in U.S. healthcare
FDA actions involving drugs, biologics, therapies, or safety warnings can influence treatment options, prescribing information, access, monitoring, and manufacturer responsibilities.
Who may be affected?
Patients, prescribers, pharmacists, hospitals, health plans, manufacturers, and specialty practices may be affected depending on the product and indication.
What to watch next
- Read the FDA announcement and product labeling or safety communication.
- Watch for indication, eligibility, safety, supply, or access details.
- Look for payer and clinical-guideline updates after the federal action.
- Do not treat a news summary as prescribing guidance.
Key takeaway
This is a developing medical-news item selected for recency, U.S. relevance, potential impact, source quality, and independent coverage where available. The original source remains the authority for exact clinical, regulatory, safety, coverage, or policy details.
Frequently asked questions
Is this article medical advice?
No. It is a news summary based on cited public sources and is not a substitute for clinical guidance or patient-specific medical advice.
How current is this story?
The agent prioritizes articles published within its configured hot-news window and rejects older stories from automatic publication.
How is a topic selected?
Stories are ranked using freshness, U.S. relevance, potential healthcare impact, source authority, and corroboration across separate sources.
Sources
Primary source: Who can be licensed as a physician? Not AI — AMA Press Releases.